Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma

doi:10.4254/wjh.v6.i9.670

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 9

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6515)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

403

WORD

303

HTML

3130

Figures (1-1)

225

Tables (1-4)

232

Sum=4293

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

956

Download

1266

Sum=2222

Sep 27, 2014 (publication date) through Jan 5, 2025

Times Cited of This Article

Times Cited (29)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Hepatol. Sep 27, 2014; 6(9): 670-676
Published online Sep 27, 2014. doi: 10.4254/wjh.v6.i9.670

Table 1 Baseline patient characteristics n (%)

Variables	Number of patients
Gender	Male	30 (81)
Gender	Female	7 (19)
Age (yr)	> 70	19 (51)
Age (yr)	≤ 70	18 (49)
Child-pugh class	A	33 (89)
Child-pugh class	B	4 (11)
Etiology	HCV	20 (54)
	HBV	11 (30)
	Others	6 (16)
TNM stage	III	16 (43)
	IVa	8 (22)
	IVb	13 (35)
Previous therapies	Yes	31 (84)
Previous therapies	No	6 (16)
AFP (ng/mL)	> 100	20 (54)
AFP (ng/mL)	≤ 100	17 (46)
DCP (mAU/mL)^a	> 1000	20 (59)
DCP (mAU/mL)^a	≤ 1000	14 (41)
Initial dose of sorafenib (mg/d)	800	21 (57)
Initial dose of sorafenib (mg/d)	< 800	16 (43)
Nursing intervention	Yes	24 (65)
Nursing intervention	No	13 (35)

^aDCP values were not available for 3 cases; TNM: Tumor-Node-Metastasis staging system; AFP: α-fetoprotein; DCP: Des-gamma-carboxy prothrombin; HBV: Hepatitis B virus; HCV: Hepatitis C virus.

Citation: Shomura M, Kagawa T, Shiraishi K, Hirose S, Arase Y, Koizumi J, Mine T. Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma. World J Hepatol 2014; 6(9): 670-676
URL: https://www.wjgnet.com/1948-5182/full/v6/i9/670.htm
DOI: https://dx.doi.org/10.4254/wjh.v6.i9.670